Literature DB >> 16724623

Chronic urticaria: pathophysiology and etiology, or the what and why.

Alan L Schocket1.   

Abstract

Chronic urticaria (CU) is a relatively common but vexing disease. The pathophysiology is based on the cutaneous mast cell release of mediators, predominantly histamine. Release can be induced via specific immunoglobulin E (IgE), components of complement activation and nonspecifically by various compounds including endogenous peptides, endorphins, and enkephalins. In >30% of CU patients, autoimmune phenomena have been found, characterized by positive autologous serum skin test, antibodies to the alpha-subunit of the basophil IgE receptor, to IgE itself, and, perhaps, the most clinically relevant, thyroid autoimmunity. Studies suggest that the products of the activated immune system can lower the cutaneous mast cell release threshold, possibly allowing activation by endogenous compounds. The resulting release of mediators produces the clinical picture of recurrent hives. Although the goal of management of CU is the identification of a treatable cause, in most CU patients, especially adults, a cause is not frequently found. Identified causes include drugs, foods, infections, immune complex production leading to urticarial vasculitis, autoantibody production, and underlying autoimmune disease, particularly autoimmune thyroiditis. The treatment of the thyroiditis with suppressive doses of thyroid hormone often results in the remission of the CU. Given the marginally effective and sometimes dangerous medical therapy available for CU, a systematic and thorough approach to identify a treatable cause in difficult CU patients is warranted.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16724623

Source DB:  PubMed          Journal:  Allergy Asthma Proc        ISSN: 1088-5412            Impact factor:   2.587


  10 in total

Review 1.  Urticaria Guidelines: Consensus and Controversies in the European and American Guidelines.

Authors:  Lauren M Fine; Jonathan A Bernstein
Journal:  Curr Allergy Asthma Rep       Date:  2015-06       Impact factor: 4.806

2.  Generalised pruritus as a presentation of Grave's disease.

Authors:  Ce Tan; Ky Loh
Journal:  Malays Fam Physician       Date:  2013-04-30

Review 3.  Aeroallergens in Atopic Dermatitis and Chronic Urticaria.

Authors:  Albert C Chong; Won Jong Chwa; Peck Y Ong
Journal:  Curr Allergy Asthma Rep       Date:  2022-04-01       Impact factor: 4.806

4.  Urticaria in a Pediatric Population: A Portuguese Single-Center Cohort Report.

Authors:  Inês Coelho; Bárbara Neto; Diana Bordalo; Sylvia Jacob
Journal:  Cureus       Date:  2022-07-08

Review 5.  Pathogenesis of chronic urticaria: an overview.

Authors:  Sanjiv Jain
Journal:  Dermatol Res Pract       Date:  2014-07-10

Review 6.  IgE-Related Chronic Diseases and Anti-IgE-Based Treatments.

Authors:  Arnau Navinés-Ferrer; Eva Serrano-Candelas; Gustavo-J Molina-Molina; Margarita Martín
Journal:  J Immunol Res       Date:  2016-12-21       Impact factor: 4.818

7.  Does omalizumab treatment affect serum dehydroepiandrosterone sulphate levels in chronic idiopathic urticaria?

Authors:  Atıl Avcı; Deniz Avcı; Ragip Ertas; Mustafa Atasoy; Cigdem Karakukcu; Efşan Yontar; Yilmaz Ulas; Kemal Ozyurt
Journal:  Postepy Dermatol Alergol       Date:  2019-02-22       Impact factor: 1.837

Review 8.  Guideline of Chronic Urticaria Beyond.

Authors:  Lauren M Fine; Jonathan A Bernstein
Journal:  Allergy Asthma Immunol Res       Date:  2016-09       Impact factor: 5.764

Review 9.  Position statement for the use of omalizumab in the management of chronic spontaneous urticaria in Indian patients.

Authors:  Kiran Godse; Murlidhar Rajagopalan; Mukesh Girdhar; Sanjiv Kandhari; Bela Shah; Prashant N Chhajed; Sushil Tahiliani; D S Krupa Shankar; Vijay Somani; Vijay Zawar
Journal:  Indian Dermatol Online J       Date:  2016 Jan-Feb

10.  The overlap syndrome of urticaria and gastroesophageal reflux disease.

Authors:  Ernesto Aitella; Fabio De Bartolomeis; Alfonso Savoia; Massimo Fabiani; Marco Romano; Corrado Astarita
Journal:  PLoS One       Date:  2018-11-20       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.